December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ana I. Velázquez Mañana: My highlight of WCLC24
Sep 9, 2024, 10:33

Ana I. Velázquez Mañana: My highlight of WCLC24

Ana I. Velázquez Mañana shared a post by Estela Rodriguez on X, adding:

“My highlight of WCLC24 here
After years of admiring & reading the work of the Boricua Ciencias Médicas UPR grad who “MADE it” — as faculty Harvard Medical School, Mass General Brigham, as a researcher focused on Lung Cancer screening in Latinos & Puerto Rico, who is a mentor to so many, and a champion of diversity & inclusion — I finally met him!

And the best part is that Narjust Florez is even nicer than I imagined.”

Quoting Estela Rodriguez:

“Boricuas at WCLC24 IASLC – with Narjust Florez,  Mass General Brigham, Ana I. Velázquez Mañana, UCSF Helen Diller Family Comprehensive Cancer Center.

Missing Coral Olazagasti, Sylvester Comprehensive Cancer Center, Joel Rivera Concepcion, Duke Cancer, Latinos In Oncology.”

Image

Source:  Estela Rodriguez/X and Ana I. Velázquez Mañana/X

Ana Velázquez Mañana is an Assistant Professor of Medicine in the UCSF Division of Hematology/Oncology at Zuckerberg San Francisco General and a thoracic oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center. She serves as Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Trainees of the UCSF Helen Diller Family Comprehensive Cancer Center and co-chairs the UCSF Department of Medicine Fellowship Diversity Committee. Her research, advocacy, and education efforts are focused on promoting and advancing health equity and workforce diversity.

Estela (Estelamari)  Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.